½ÃÀ庸°í¼­
»óǰÄÚµå
1631119

°¡±Ý¿ë ¹é½Å ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® º¸°í¼­ : ¹é½Å À¯Çüº°, ¿ëµµº°, Áúȯ À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº° ¿¹Ãø(2025-2030³â)

Poultry Vaccines Market Size, Share & Trends Analysis Report By Vaccine Type, By Application, By Disease Type, By Route of Administration, By Distribution Channels, By Region, And Segment Forecasts, 2025 - 2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Grand View Research | ÆäÀÌÁö Á¤º¸: ¿µ¹® 120 Pages | ¹è¼Û¾È³» : 2-10ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

°¡±Ý·ù ¹é½Å ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ

°¡±Ý¿ë ¹é½Å ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â¿¡´Â 36¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2030³â¿¡ °ÉÃÄ CAGR 7.60%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

½ÃÀåÀ» °ßÀÎÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î´Â °¡±ÝÀ°°ú °è¶õÀÇ ¼Òºñ·® Áõ°¡, Á¶·ùÁúº´ÀÇ À¯Çà, ÁÖ¿ä½ÃÀå¿¡¼­ÀÇ °¡±ÝÀα¸ Áõ°¡ µîÀÌ ÀÖ½À´Ï´Ù. OECD-FAO Agricultural Àü¸Á¿¡ µû¸£¸é ¹Ì±¹ÀÇ 2020³â ´ß°í±â ¼Òºñ·®Àº 1,916¸¸ 9,000ÅæÀ̾ú½À´Ï´Ù. ÀÌ ¼Òºñ·®Àº ÇâÈÄ ¼ö³â°£ Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

COVID-19ÀÇ ´ëÀ¯ÇàÀº ¼Òºñ ħü, Áü½Â °øÅë °¨¿°¿¡ ´ëÇÑ ¿ì·Á Áõ°¡, ¸ÅÃâ ºÎÁø µî °¡±Ý·ù »ê¾÷¿¡ ¸î °¡Áö °úÁ¦¸¦ °¡Á®¿Ô½À´Ï´Ù. ¿¹¸¦ µé¾î, ÀÌÄÚ³ë¹Í ŸÀÓÁî¿¡ µû¸£¸é 2020³â 3¿ù °í±â, »ý¼±, °è¶õ, ´ß°í±â ¼Òºñ °¨¼Ò·Î ´ß°í±â °¡°ÝÀº 70%³ª ±Þ¶ôÇß½À´Ï´Ù. ±×·¯³ª À¯ÇàÀº µ¿¹°ÀÇ Áúº´¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡¿Í ¾ÈÀüÇÏ°í °Ç°­ÇÑ ´ß°í±â Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡·Î À̾îÁ³½À´Ï´Ù. °¡±Ý·ù ³óÀåÀº °Ç°­ÇÑ ·¹À̾î, À°°è, ºê¸®´õ °¡ÃàÀ» È®º¸ÇؾßÇϱ⠶§¹®¿¡ °¡±Ý·ù ¹é½Å Á¦Á¶¾÷ü¿¡°Ô ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ½ÇÁ¦·Î 2021³â 4¿ù, Hester Biosciences Ltd.ÀÇ CEO °â MD´Â °¡±Ý·ù ¹é½Å ½ÃÀåÀÌ COVID ÀÌÈÄ Å©°Ô ¼ºÀåÇÒ °ÍÀ̶ó°í ¸»Çß½À´Ï´Ù.

°Ô´Ù°¡ »ì¸ð³Ú¶ó º¤ÅÍ ¹é½Å°ú °°Àº °¡±Ý·ù¸¦ ±«»ç¼º Àå¿°À¸·ÎºÎÅÍ º¸È£ÇÏ´Â »õ·Î¿î ¹é½ÅÀÇ ÃâÇöÀº ÀÌ ½ÃÀå¿¡ ¼ºÀå ±â¹ÝÀ» Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. °Ô´Ù°¡ ¿¬±¸±â°üÀ̳ª ´ëÇп¡ ÀÇÇÑ °¡±Ý¿ë ¹é½ÅÀÇ »ç¿ë·® Áõ°¡°¡ ¹é½ÅÁ¢Á¾ °è¹ß ÇÁ·Î±×·¥°ú ÇÔ²² ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, 2019³â 7¿ù, ÀεµÀÇ ¸¶µÎ¶óÀÌ¿¡ º»»ç¸¦ µÐ ¼öÀÇ´ëÇÐ ¿¬±¸¼Ò´Â ³ó¾÷ Á¾»çÀÚ°¡ »ó´çÇÑ ¼Õ½ÇÀ» ÀÔ´Â °ÍÀ» ±¸Çϱâ À§ÇØ ÁÖ·Î ´ßÀÎ °¡±Ý·ù ¹é½Å Á¢Á¾À» ½ÃÀÛÇß½À´Ï´Ù.

°¡±Ý·ù ¹é½ÅÀÇ ±â¼úÀû Áøº¸, µ¿¹°¼º ´Ü¹éÁú¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, ½Äǰ ¾ÈÀü, µ¿¹° º¹Áö, ¹Ì»ý¹° ³»¼º¿¡ ´ëÇÑ ¿ì·Á, Á¶·ù ÀÇÇп¡ ´ëÇÑ ÁÖ¸ñ Áõ°¡, Áúº´ Ä¡·á¿¡¼­ ¿¹¹æÀ¸·ÎÀÇ ÀüȯÀº ½ÃÀå ¼ºÀå ±âȸ¸¦ âÃâÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ±âŸ ¿äÀÎÀÇ ÀϺÎÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, ÇǺê·Î µ¿¹° Çコ ÄÚÆÛ·¹À̼ÇÀÇ TAbic Vaccines LineÀº ´ºÄ³½½º´, Àü¿°¼º ±â°üÁö¿° ¹× ±âŸ °¡±Ýº´À¸·ÎºÎÅÍ °¡±ÝÀ» º¸È£Çϱâ À§ÇÑ 25°¡Áö ÀÌ»óÀÇ ¹é½ÅÀ¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù.

°¡±Ý·ù ¹é½Å ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

  • °¡±Ý·ù¿¡¼­ °¨¿°ÁõÀÇ ¸¸¿¬ÀÌ Áõ°¡Çϰí ÀÌ ºÎ¹®¿¡¼­ÀÇ Á¦Ç° °³¹ßÀº ½ÃÀå¿¡ ¼ºÀå ±âȸ¸¦ °¡Á®¿Ã °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • Á¦Ç°º°·Î ¾àµ¶»ý ¹é½ÅÀº ºñ±³Àû ³·Àº Á¦Á¶ ºñ¿ë°ú ±ä º¸È£ ±â°£À¸·Î 2024³â ÃÖ´ë ÆÇ¸Å Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
  • °è¶õ ³«ÇÏ ÁõÈıº(EDS) Áúº´ À¯ÇüÀº ¹ÙÀÌ·¯½º¼º Áúº´À» ¿¹¹æÇÏ´Â ºÒȰ¼ºÈ­ ¹é½ÅÀÇ »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ ¿¹Ãø ±â°£ µ¿¾È À¯¸®ÇÑ ¼ºÀå·üÀ» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
  • MSD Vet Manual¿¡ ÀÇÇϸé, EDS ¹é½ÅÀº ´ºÄ³½½º´ µîÀÇ ´Ù¸¥ ¹é½Å°ú Á¶ÇÕÇÏ¿© Åõ¿©ÇÏ´Â °Íµµ °¡´ÉÇϰí, ±× ¶§¹®¿¡ ä¿ëÀ²ÀÌ ³ô¾ÆÁö°í ÀÖ´Ù
  • °¡±Ý·ùÀÇ °Ç°­À» È®º¸ÇÏ°í ³óÀåÀÇ »ý»ê¼ºÀ» Çâ»ó½Ã۱â À§ÇØ ºê¸®´õ ³óÀå¿¡¼­ÀÇ ¹é½Å »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®¿¡ 2024³â¿¡´Â ºê¸®´õ ¿ëµµ ºÎ¹®ÀÌ ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù.
  • ºÏ¹ÌÀÇ °¡±Ý¿ë ¹é½Å ½ÃÀåÀº ¼¼°è ½ÃÀåÀ» µ¶Á¡Çϰí 2024³â¿¡´Â ÃÑ ¸ÅÃâ Á¡À¯À²ÀÇ 37.7%¸¦ Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷ÀÇ Á¸Àç, µ¿¹°¼º ´Ü¹éÁú ¼Òºñ Áõ°¡, ±â¼úÀÇ Áøº¸ µî ¸¹Àº ¿äÀÎ ¶§¹®ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °¡±Ý¿ë ¹é½Å ½ÃÀåÀÇ º¯¼ö, µ¿Çâ, ¹üÀ§

  • ½ÃÀå °èÅëÀÇ Àü¸Á
    • ¸ð ½ÃÀå Àü¸Á
    • °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
  • ½ÃÀå ¿ªÇÐ
    • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
    • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
  • °¡±Ý¿ë ¹é½Å ½ÃÀå ºÐ¼® Åø
    • »ê¾÷ ºÐ¼® - Porter's Five Forces ºÐ¼®
    • PESTEL ºÐ¼®
  • ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
  • °¡°Ý ºÐ¼®
  • COVID-19ÀÇ ¿µÇ⠺м®

Á¦4Àå °¡±Ý¿ë ¹é½Å ½ÃÀå : ¿ëµµº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • °¡±Ý¿ë ¹é½Å ½ÃÀå : ¿ëµµ º¯µ¿ ºÐ¼®
  • ¿ëµµº° °¡±Ý¿ë ¹é½Å ½ÃÀå Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®
  • ºê·Ñ¸®¾î
  • ·¹À̾î
  • ºê¸®´õ

Á¦5Àå °¡±Ý¿ë ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • °¡±Ý¿ë ¹é½Å ½ÃÀå : ¹é½Å À¯Çü º¯µ¿ ºÐ¼®
  • ¹é½Å À¯Çüº°°¡±Ý¿ë ¹é½Å ½ÃÀå Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®
  • ¾àµ¶/»ý±Õ
  • ºÒȰ¼ºÈ­(»ç±Õ)
  • ±âŸ ¹é½Å

Á¦6Àå °¡±Ý¿ë ¹é½Å ½ÃÀå : Áúº´ À¯Çüº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • °¡±Ý¿ë ¹é½Å ½ÃÀå : Áúº´ À¯Çü º¯µ¿ ºÐ¼®
  • Áúº´ À¯Çüº° °¡±Ý¿ë ¹é½Å ½ÃÀå Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®
  • °¨¿°¼º ±â°üÁö¿°
  • °¨¿°¼º ºÎ¸£»ìº´
  • °¨¿°¼º ÈĵΠ±â°ü¿°
  • ¿¡±× µå·Ó ÁõÈıº
  • ¾Æµ¥³ë¹ÙÀÌ·¯½º
  • ¿À¸®¹ÙÀÌ·¯½º¼º Àå¿°
  • ºÀÀÔü °£¿°
  • Ä۽õãÁõ
  • Á¶·ù ÀÎÇ÷翣ÀÚ
  • ¸¶·ºº´
  • ´ºÄ³½½º´
  • »ì¸ð³Ú¶ó
  • Á¶·ù ³úô¼ö¿°
  • °¡±Ý ÄÝ·¹¶ó

Á¦7Àå °¡±Ý¿ë ¹é½Å ½ÃÀå : Åõ¿© °æ·Îº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • °¡±Ý¿ë ¹é½Å ½ÃÀå : Åõ¿© °æ·Î º¯µ¿ ºÐ¼®
  • Åõ¿© °æ·Îº° °¡±Ý¿ë ¹é½Å ½ÃÀå Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®
  • ÁÖ»ç
  • ºñ°­³»

Á¦8Àå °¡±Ý¿ë ¹é½Å ½ÃÀå : À¯Åë ä³Îº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • ºÎ¹® ´ë½Ãº¸µå
  • °¡±Ý¿ë ¹é½Å ½ÃÀå : À¯Åë ä³Î º¯µ¿ ºÐ¼®
  • À¯Åë ä³Îº°°¡±Ý¿ë ¹é½Å ½ÃÀå Àü¸Á
  • 2018-2030³â ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø°ú µ¿Ç⠺м®
  • ¼Ò¸Å
  • ÀüÀÚ»ó°Å·¡
  • º´¿ø ¹× Ŭ¸®´Ð ¾à±¹

Á¦9Àå °¡±Ý¿ë ¹é½Å ½ÃÀå :Áö¿ªº°, ÃßÁ¤¡¤µ¿Ç⠺м®

  • Áö¿ª ´ë½Ãº¸µå
  • ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®(2018-2030³â)
  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • ¿µ±¹
    • µ¶ÀÏ
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ½º¿þµ§
    • µ§¸¶Å©
    • ³ë¸£¿þÀÌ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • Çѱ¹
    • ű¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ¶óƾ¾Æ¸Þ¸®Ä«
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ·Î½º¾ØÁ©·¹½ºÀÇ ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • ³²¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • Äí¿þÀÌÆ®
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • ±â¾÷ ºÐ·ù
  • ÁÖ¿ä ½ÃÀå ÁøÃâ±â¾÷¿¡ ÀÇÇÑ ÃÖ±ÙÀÇ µ¿Çâ°ú ¿µÇ⠺м®
  • ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®(2024³â)
  • ±â¾÷ °³¿ä
    • Boehringer Ingelheim International GmbH
    • Zoetis Services LLC
    • Vaxxinova International BV
    • Merck & Co., Inc.
    • Calier
    • KM Biologics(Meiji Animal Health)
    • Elanco
    • Hester Biosciences Limited
    • Ceva Sante Animale
    • Phibro Animal Health Corporation
KTH 25.02.28

Poultry Vaccines Market Growth & Trends:

The global poultry vaccines market size is expected to reach USD 3.66 billion in 2030 and is projected to grow at a CAGR of 7.60% from 2025 to 2030. The key factors driving the market include the rising consumption of poultry meat and eggs, the prevalence of avian diseases, and the increasing poultry population in key markets. According to OECD-FAO Agricultural Outlook, poultry meat consumption in the U.S. was pegged at 19,169 thousand tons in 2020. This consumption is projected to increase over the next few years.

The COVID-19 pandemic resulted in several challenges for the poultry industry including a fall in consumption, increased concerns over zoonoses, and low sales. For example, as per the Economic Times, in March 2020, the price of chicken plunged by as much as 70% due to the reduced consumption of meat, fish, eggs, and chicken. However, the pandemic also led to the rising awareness regarding diseases in animals and increasing demand for safe and healthy poultry products. This is anticipated to create opportunities for poultry vaccines manufacturers as poultry farms must ensure healthy layer, broiler, and breeder stock. In fact, in April 2021, the CEO & MD of Hester Biosciences Ltd. stated that the market for poultry vaccines is set to grow significantly post COVID.

In addition, the advent of new vaccines, such as Salmonella-vectored vaccines, which protect domesticated birds against necrotic enteritis is anticipated to provide a growth platform to this market. In addition, the rising usage of poultry vaccines by research institutes and colleges, along with vaccination awareness programs, is fueling the growth of the market. For instance, in July 2019, the Veterinary College and Research Institute based in Madurai, India started vaccinating domesticated birds, predominantly chickens, to save farmers from suffering significant losses.

Technological advancements in poultry vaccines, rising demand for animal protein, concerns over food safety, animal welfare, and microbial resistance, increased focus on avian healthcare, and shift from treatment to the prevention of diseases are some of the other factors anticipated to create growth opportunities in the market. For instance, the TAbic Vaccines Line by Phibro Animal Health Corporation comprises 25+ vaccines for poultry for protection against Newcastle disease, infectious bronchitis, and other poultry diseases.

Poultry Vaccines Market Report Highlights:

  • The increasing prevalence of infectious diseases in poultry and product developments in the field are anticipated to create growth opportunities in the market
  • By product, attenuated live vaccines held the largest revenue share in 2024 owing to their relatively low production cost and long duration of protection
  • The Egg Drop Syndrome (EDS) disease type segment is expected to register a lucrative growth rate over the forecast period due to the growing use of inactivated vaccines to prevent viral disease
  • As per the MSD Vet Manual, EDS vaccines can also be given in combination with other vaccines, such as those for Newcastle disease, thus increasing their adoption rate
  • The breeder application segment dominated the market in 2024 due to the increasing use of vaccines at breeder farms to secure the health of the poultry and increase farm's productivity
  • The North America poultry vaccines market dominated the global market and accounted for 37.7% of the total revenue share in 2024. This is due to a number of factors including the existence of major market participants, rising animal protein consumption, and advancements in technology.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Segment Definitions
    • 1.2.1. Application
    • 1.2.2. Vaccine Type
    • 1.2.3. Disease type
    • 1.2.4. Route of Administration
    • 1.2.5. Distribution Channel
    • 1.2.6. Regional Scope
    • 1.2.7. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Application
    • 2.2.2. Vaccine Type
    • 2.2.3. Disease Type
    • 2.2.4. Route of Administration
    • 2.2.5. Distribution Channel
  • 2.3. Regional outlook
  • 2.4. Competitive Insights

Chapter 3. Poultry Vaccines Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Improvements in vectored and combination vaccinations
      • 3.2.1.2. Increasing prevalence of poultry diseases
      • 3.2.1.3. R&D/ Technological advancements
      • 3.2.1.4. Initiatives by market participants
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. Cost of vaccination
      • 3.2.2.2. Lack of awareness
  • 3.3. Poultry Vaccines Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Bargaining power of suppliers
      • 3.3.1.2. Bargaining power of buyers
      • 3.3.1.3. Threat of substitutes
      • 3.3.1.4. Threat of new entrants
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Economic landscape
      • 3.3.2.3. Social landscape
      • 3.3.2.4. Technological landscape
      • 3.3.2.5. Environmental landscape
      • 3.3.2.6. Legal landscape
      • 3.3.2.7. Estimated Poultry Population by key Species, key Country, 2018-2024
  • 3.4. Regulatory Framework
  • 3.5. Pricing Analysis
  • 3.6. COVID-19 impact Analysis

Chapter 4. Poultry Vaccines Market: Application Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Poultry Vaccines Market: Application Movement Analysis
  • 4.3. Poultry Vaccines Market by Application Outlook (USD Million)
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 4.5. Brolier
    • 4.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.6. Layer
    • 4.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 4.7. Breeder
    • 4.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 5. Poultry Vaccines Market: Vaccine Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Poultry Vaccines Market: Vaccine Type Movement Analysis
  • 5.3. Poultry Vaccines Market by Vaccine Type Outlook (USD Million)
  • 5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 5.5. Modified/ Attenuated Live
    • 5.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.6. Inactivated (Killed)
    • 5.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 5.7. Other Vaccines
    • 5.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 6. Poultry Vaccines Market: Disease Type Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. Poultry Vaccines Market: Disease type Movement Analysis
  • 6.3. Poultry Vaccines Market by Disease type Outlook (USD Million)
  • 6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 6.5. Infectious Bronchitis
    • 6.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.6. Infectious Bursal Diseases
    • 6.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.7. Infectious Laryngotracheitis
    • 6.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.8. Egg Drop Syndrome
    • 6.8.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.9. Adenovirus
    • 6.9.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.10. Duck Viral Enteritis
    • 6.10.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.11. Inclusion Body Hepatitis
    • 6.11.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.12. Coccidiosis
    • 6.12.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.13. Avian Influenza
    • 6.13.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.14. Marek's Disease
    • 6.14.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.15. Newcastle Disease
    • 6.15.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.16. Salmonella
    • 6.16.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.17. Avian Encephalomyelitis
    • 6.17.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 6.18. Fowl Cholera
    • 6.18.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 7. Poultry Vaccines Market: Route of Administration Estimates & Trend Analysis

  • 7.1. Segment Dashboard
  • 7.2. Poultry Vaccines Market: Route of Administration Movement Analysis
  • 7.3. Poultry Vaccines Market by Route of Administration Outlook (USD Million)
  • 7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 7.5. Injectable
    • 7.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.6. Intranasal
    • 7.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 8. Poultry Vaccines Market: Distribution Channel Estimates & Trend Analysis

  • 8.1. Segment Dashboard
  • 8.2. Poultry Vaccines Market: Distribution Channel Movement Analysis
  • 8.3. Poultry Vaccines Market by Distribution Channel Outlook (USD Million)
  • 8.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
  • 8.5. Retail
    • 8.5.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.6. E-Commerce
    • 8.6.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 8.7. Hospital/Clinic Pharmacies
    • 8.7.1. Market Estimates And Forecast, 2018 - 2030 (USD Million)

Chapter 9. Poultry Vaccines Market: Regional Estimates & Trend Analysis

  • 9.1. Regional Dashboard
  • 9.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 9.3. North America
    • 9.3.1. U.S.
      • 9.3.1.1. Key country dynamics
      • 9.3.1.2. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.3.2. Canada
      • 9.3.2.1. Key country dynamics
      • 9.3.2.2. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.3.3. Mexico
      • 9.3.3.1. Key country dynamics
      • 9.3.3.2. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.4. Europe
    • 9.4.1. UK
      • 9.4.1.1. Key country dynamics
      • 9.4.1.2. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.2. Germany
      • 9.4.2.1. Key country dynamics
      • 9.4.2.2. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.3. France
      • 9.4.3.1. Key country dynamics
      • 9.4.3.2. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.4. Italy
      • 9.4.4.1. Key country dynamics
      • 9.4.4.2. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.5. Spain
      • 9.4.5.1. Key country dynamics
      • 9.4.5.2. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.6. Sweden
      • 9.4.6.1. Key country dynamics
      • 9.4.6.2. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.7. Denmark
      • 9.4.7.1. Key country dynamics
      • 9.4.7.2. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.8. Norway
      • 9.4.8.1. Key country dynamics
      • 9.4.8.2. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.4.9. Rest of Europe
      • 9.4.9.1. Key country dynamics
      • 9.4.9.2. Rest of Europe market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.5. Asia Pacific
    • 9.5.1. Japan
      • 9.5.1.1. Key country dynamics
      • 9.5.1.2. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.2. China
      • 9.5.2.1. Key country dynamics
      • 9.5.2.2. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.3. India
      • 9.5.3.1. Key country dynamics
      • 9.5.3.2. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.4. Australia
      • 9.5.4.1. Key country dynamics
      • 9.5.4.2. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.5. South Korea
      • 9.5.5.1. Key country dynamics
      • 9.5.5.2. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.6. Thailand
      • 9.5.6.1. Key country dynamics
      • 9.5.6.2. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.5.7. Rest of Asia-Pacific
      • 9.5.7.1. Key country dynamics
      • 9.5.7.2. Rest of Asia-Pacific market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.6. Latin America
    • 9.6.1. Brazil
      • 9.6.1.1. Key country dynamics
      • 9.6.1.2. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.2. Argentina
      • 9.6.2.1. Key country dynamics
      • 9.6.2.2. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.6.3. Rest of LA
      • 9.6.3.1. Key country dynamics
      • 9.6.3.2. Rest of LA market estimates and forecasts 2018 to 2030 (USD Million)
  • 9.7. MEA
    • 9.7.1. South Africa
      • 9.7.1.1. Key country dynamics
      • 9.7.1.2. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.2. Saudi Arabia
      • 9.7.2.1. Key country dynamics
      • 9.7.2.2. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.3. UAE
      • 9.7.3.1. Key country dynamics
      • 9.7.3.2. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.4. Kuwait
      • 9.7.4.1. Key country dynamics
      • 9.7.4.2. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
    • 9.7.5. Rest of MEA
      • 9.7.5.1. Key country dynamics
      • 9.7.5.2. Rest of MEA market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 10. Competitive Landscape

  • 10.1. Company Categorization
  • 10.2. Recent Developments & Impact Analysis by Key Market Participants
  • 10.3. Company Market Share Analysis, 2024
  • 10.4. Company overview
    • 10.4.1. Boehringer Ingelheim International GmbH
      • 10.4.1.1. Company Overview
      • 10.4.1.2. Financial performance
      • 10.4.1.3. Product benchmarking
      • 10.4.1.4. Strategic initiatives
    • 10.4.2. Zoetis Services LLC
      • 10.4.2.1. Company Overview
      • 10.4.2.2. Financial performance
      • 10.4.2.3. Product benchmarking
      • 10.4.2.4. Strategic initiatives
    • 10.4.3. Vaxxinova International BV
      • 10.4.3.1. Company Overview
      • 10.4.3.2. Financial performance
      • 10.4.3.3. Product benchmarking
      • 10.4.3.4. Strategic initiatives
    • 10.4.4. Merck & Co., Inc.
      • 10.4.4.1. Company Overview
      • 10.4.4.2. Financial performance
      • 10.4.4.3. Product benchmarking
      • 10.4.4.4. Strategic initiatives
    • 10.4.5. Calier
      • 10.4.5.1. Company Overview
      • 10.4.5.2. Financial performance
      • 10.4.5.3. Product benchmarking
      • 10.4.5.4. Strategic initiatives
    • 10.4.6. KM Biologics (Meiji Animal Health)
      • 10.4.6.1. Company Overview
      • 10.4.6.2. Financial performance
      • 10.4.6.3. Product benchmarking
      • 10.4.6.4. Strategic initiatives
    • 10.4.7. Elanco
      • 10.4.7.1. Company Overview
      • 10.4.7.2. Financial performance
      • 10.4.7.3. Product benchmarking
      • 10.4.7.4. Strategic initiatives
    • 10.4.8. Hester Biosciences Limited
      • 10.4.8.1. Company Overview
      • 10.4.8.2. Financial performance
      • 10.4.8.3. Product benchmarking
      • 10.4.8.4. Strategic initiatives
    • 10.4.9. Ceva Sante Animale
      • 10.4.9.1. Company Overview
      • 10.4.9.2. Financial performance
      • 10.4.9.3. Product benchmarking
      • 10.4.9.4. Strategic initiatives
    • 10.4.10. Phibro Animal Health Corporation
      • 10.4.10.1. Company Overview
      • 10.4.10.2. Financial performance
      • 10.4.10.3. Product benchmarking
      • 10.4.10.4. Strategic initiatives
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦